Short answer
RECURSION PHARMACEUTICALS, INC. (RXRX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Forward-looking statement caution covering Tempus Agreement and Restated Agreement performance.
RECURSION PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Forward-looking statement caution covering Tempus Agreement and Restated Agreement performance
- Actual outcomes may differ materially because of identified risks and uncertainties
- Investors should rely on historical results and SEC-filed risk factors rather than projections alone
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.3 contains presentation materials from Recursion’s August 5, 2026 earnings call
- Investor-relevant operating and financial details require review of the attached presentation
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $7.7M, down from $19.2M; lower Roche/Genentech recognition reflects completed prior-period project phases
- Genentech exercised first neuroscience target option, validating Recursion’s platform and initiating a small-molecule discovery program
- Collaboration economics include up to 40 programs, each with potential milestones exceeding $300M plus tiered royalties up to high single digits
- Cash $556.8M and runway into early 2028; 2026 cash operating expense guidance reduced to below $375M
- REC-7735 IND cleared, with Phase 1/2 ZINNIA trial planned for 2H26 and stated mutant selectivity above 100-fold
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RECURSION PHARMACEUTICALS, INC. 8-K filings
Get the next RXRX 8-K as it lands
Follow RXRX for push alerts, or ask the research agent what this filing means.